Chikungunya Virus, Metabolism, and Circadian Rhythmicity Interplay in Phagocytic Cells

• Published in: Metabolites Vol. 13; no. 11; p. 1143
• Main Authors: Alvarez-García, Linamary, Sánchez-García, F. Javier, Vázquez-Pichardo, Mauricio, Moreno-Altamirano, M. Maximina
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-11-2023
• Subjects: Care and treatment; Chikungunya virus; circadian immunovirometabolism; Circadian rhythm; Circadian rhythms; Diagnosis; Disease transmission; Drug development; Health aspects; Host-pathogen interactions; Immune system; Immunosuppressive agents; Innate immunity; Macrophages; metabolic reprogramming; Metabolism; Metabolites; Monocytes; Pathogenicity; Phagocytes; Tricarboxylic acid cycle; Viral infections; Viruses; Mexico
• ISSN: 2218-1989; 2218-1989
• DOI: 10.3390/metabo13111143

Chikungunya virus (CHIKV) is transmitted to humans by mosquitoes of the genus Aedes, causing the chikungunya fever disease, associated with inflammation and severe articular incapacitating pain. There has been a worldwide reemergence of chikungunya and the number of cases increased to 271,006 in 2022 in the Americas alone. The replication of CHIKV takes place in several cell types, including phagocytic cells. Monocytes and macrophages are susceptible to infection by CHIKV; at the same time, they provide protection as components of the innate immune system. However, in host–pathogen interactions, CHIKV might have the ability to alter the function of immune cells, partly by rewiring the tricarboxylic acid cycle. Some viral evasion mechanisms depend on the metabolic reprogramming of immune cells, and the cell metabolism is intertwined with circadian rhythmicity; thus, a circadian immunovirometabolism axis may influence viral pathogenicity. Therefore, analyzing the interplay between viral infection, circadian rhythmicity, and cellular metabolic reprogramming in human macrophages could shed some light on the new field of immunovirometabolism and eventually contribute to the development of novel drugs and therapeutic approaches based on circadian rhythmicity and metabolic reprogramming.